Exit opportunities are available for savvy investors in India, and market professionals say prospects are good in the long term. But GPs are likely to continue to find the near future difficult
CDH Investments and CCB International have sold their stakes in Harmonicare Medical Holdings, operator of 11 women and children’s hospitals in China, to Taikang Insurance Group for HK$815.2 million ($105.1 million).
CDH Investments has made another partial exit from Chinese pork producer WH Group, selling an approximately 6.83% stake for HK$6.25 billion ($806 million).
Crescent Capital Partners has agreed to sell a 14.9% stake in Australian financial services provider ClearView Wealth to Sony Life Insurance for approximately A$145 million ($111 million).
Pacific Equity Partners (PEP) has completed its exit from Link Group, selling its stake in the Australian financial data and fund administration services provider alongside several other shareholders in a deal said to be worth A$872.3 million ($670 million).
Apax Partners has made a partial exit from Indian non-banking finance company (NBFC) Cholamandalam Investment & Finance, generating proceeds of $102 million.
The Blackstone Group has completed its purchase of Indian IT services provider Mphasis from Hewlett Packard, raising its stake in the company to 60% for a total payment of about $825 million.
The Carlyle Group has fully exited its remaining stake in Australian ports operator Qube Logistics for a reported A$350 million ($263 million).
CDH Investments, the largest PE shareholder in WH Group, will raise HK$9.25 billion ($1.19 billion) by exiting a 10.6% stake in the Chinese pork processor.
Foreign buyers and restless chaebols could help deliver more exit opportunities for private equity firms in Korea – provided it is the right asset, at the right price, at the right time
Singapore's Temasek Holdings has exited its stakes in Bharti Airtel and Intouch, telecommunications service providers based in India and Thailand respectively, to Singapore Telecommunications (SingTel) for a total of S$2.5 billion ($1.8 billion).
ICICI Venture has exited nearly all of its remaining stake in Indian staffing services company TeamLease for INR1 billion ($15 million).
The Blackstone Group has sold down stock worth INR2.9 billion ($4.3 million) in India-listed garment manufacturer Gokaldas Exports as part of an ongoing exit from the company.
New Silk Route (NSR) has exited its remaining stake in Indian logistics firm VRL Logistics.
Nalanda Capital has sold shares worth INR4.4 billion ($65.1 million) in Indian industrial materials company Carborundum Universal.
CVC Capital Partners has offered to buy out Hong Kong-listed Nirvana Asia, Asia’s largest funeral services firm, in a cash and stock swap deal worth $1.1 billion.
KKR will make a partial exit from Chinese car dealership China Greenland Rundong Auto as the company’s founder and president sealed agreements that will see him regain majority control and trigger a mandatory buyout offer.
Australia’s Telstra has closed the sale of a 47.7% interest in Chinese auto services company Autohome to Ping An Insurance Group for $1.6 billion.
Creador has exited the remainder of its stake in India-based non-banking finance company Cholamandalam Investment and Finance (CIF) for INR2.2 billion ($32.5 million).
Warburg Pincus has agreed to make another partial exit from China Biologic Products, a US-listed bio-pharmaceutical developer, generating proceeds of about $308 million.
Providence Equity has sold about 3.5% of its 6.8% stake in India’s Idea Cellular for INR13.8 billion ($206.6 million).
Singapore’s GIC Private and Temasek Holdings have bought a combined $1 billion of Chinese e-commerce giant Alibaba Group’s shares, as part of an $8.9 billion share sale by Japan’s SoftBank Group.
Samara Capital has exited its stake in Indian listed oil and gas exploration services provider Asian Oilfield Services to Mumbai-based energy exploration firm Oilmax Energy for INR300 million ($4.4 million).
CDH Investments has made another partial exit from China-based drug developer Luye Pharma, generating proceeds of between HK$709 million ($91.4 million) and HK$729 million.